Literature DB >> 18251156

Survivin gene expression in chronic liver disease and hepatocellular carcinoma.

Marco Montorsi1, Marco Maggioni, Monica Falleni, Caterina Pellegrini, Matteo Donadon, Guido Torzilli, Roberto Santambrogio, Antonino Spinelli, Guido Coggi, Silvano Bosari.   

Abstract

BACKGROUND/AIMS: Survivin is an oncofetal protein involved both in cell death and cell cycle regulation. Survivin is undetectable or found at very low levels in normal differentiated tissues whereas increased expression has been observed in several human malignancies, including lung, colon and liver cancer. The aim of this study was to evaluate the diagnostic and clinical significance of Survivin expression in hepatocellular carcinoma and non-neoplastic liver tissues in a series of surgical patients.
METHODOLOGY: Survivin mRNA levels were quantitated by real time RT-PCR in 25 patients.
RESULTS: Survivin mRNA was documented in all liver tissues with significantly higher levels in neoplastic specimens (p=0.01). In non-neoplastic liver tissue, Survivin levels were correlated with activity score of chronic liver disease. Increased Survivin levels were correlated with high tumor grade (p=0.05) and vascular invasion (p= 0.005). Tumor recurrences were more frequent in patients with high Survivin levels, although the difference did not reach statistical significance.
CONCLUSIONS: Low levels of Survivin mRNA are present in normal and in non-neoplastic liver tissue. In hepatocellular carcinomas, high levels of Survivin are associated with aggressive tumor features. The prognostic significance of quantitative Survivin evaluation requires further studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18251156

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  17 in total

1.  The impact of survivin on prognosis and clinicopathology of glioma patients: a systematic meta-analysis.

Authors:  Shunzeng Lv; Congxin Dai; Yuting Liu; Ranran Shi; Zhenyu Tang; Mingzhi Han; Ruixiang Bian; Bowen Sun; Renzhi Wang
Journal:  Mol Neurobiol       Date:  2014-07-27       Impact factor: 5.590

2.  Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma.

Authors:  Xiaobo Jia; Yingtang Gao; Daokuan Zhai; Jiao Liu; Yajie Wang; L I Jing; Zhi DU
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

3.  Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population.

Authors:  Xia-Bin Li; Shi-Ning Li; Zhi-Hui Yang; Ling Cao; Fang-Lei Duan; Xing-Wang Sun
Journal:  DNA Cell Biol       Date:  2013-04-12       Impact factor: 3.311

4.  Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

Authors:  Jie Wang; Ze Lu; Bertrand Z Yeung; M Guillaume Wientjes; David J Cole; Jessie L-S Au
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

5.  Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model.

Authors:  Mengde Cao; Victor Prima; David Nelson; Stanislav Svetlov
Journal:  Cell Oncol (Dordr)       Date:  2013-04-26       Impact factor: 6.730

6.  Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin.

Authors:  Lihua Min; Yuan Ji; Latifa Bakiri; Zhixin Qiu; Jin Cen; Xiaotao Chen; Lingli Chen; Harald Scheuch; Hai Zheng; Lunxiu Qin; Kurt Zatloukal; Lijian Hui; Erwin F Wagner
Journal:  Nat Cell Biol       Date:  2012-10-07       Impact factor: 28.824

7.  Polymorphisms of BIRC5 Gene is Associated with Chronic HBV Infection in Iranian Population.

Authors:  Bita Moudi; Zahra Heidari; Hamidreza Mahmoudzadeh-Sagheb
Journal:  Indian J Clin Biochem       Date:  2019-01-02

8.  The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation.

Authors:  Xiaoyu Fu; Deming Tan; Zhouhua Hou; Zhiliang Hu; Guozhen Liu; Yi Ouyang; Fei Liu
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

9.  Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma.

Authors:  Claudia Augello; Luca Caruso; Marco Maggioni; Matteo Donadon; Marco Montorsi; Roberto Santambrogio; Guido Torzilli; Valentina Vaira; Caterina Pellegrini; Massimo Roncalli; Guido Coggi; Silvano Bosari
Journal:  BMC Cancer       Date:  2009-04-27       Impact factor: 4.430

10.  miR-338-3p is down-regulated by hepatitis B virus X and inhibits cell proliferation by targeting the 3'-UTR region of CyclinD1.

Authors:  Xiaoyu Fu; Deming Tan; Zhouhua Hou; Zhiliang Hu; Guozhen Liu
Journal:  Int J Mol Sci       Date:  2012-07-09       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.